Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation

American Journal of Transplantation

Volumn 8, Issue 7, 2008, Pages 1512-1522

  Weigt, S S ^a   Elashoff, R M ^b   Keane, M P ^c   Strieter, R M ^d   Gomperts, B N ^a   Xue, Y Y ^a   Ardehali, A ^a   Gregson, A L ^a   Kubak, B ^a   Fishbein, M C ^a   Saggar, R ^a   Ross, D J ^a   Lynch Iii, J P ^a   Zisman, D A ^a   Belperio, J A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bronchiolitis obliterans syndrome; Chemokines; Cytomegalovirus (CMV); Lung transplantation; Survival

Indexed keywords

AZATHIOPRINE; BETA CHEMOKINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; LUNG INFECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

BRONCHIOLITIS OBLITERANS; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINE CCL3; CHEMOKINES, CC; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT SURVIVAL; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; RISK ASSESSMENT; UP-REGULATION;

EID: 47249111662     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02280.x     Document Type: Article

References (51)

1. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004 17: 357 361.
2. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 34: 1094 1097.
3. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006 81: 1415 1420.
4. Reinke P, Prosch S, Kern F, Volk HD. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999 1: 157 164.
5. Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria. J Heart Lung Transplant 2002 21: 297 310.
6. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 1997 63: 414 420.
7. Ruster M, Sperschneider H, Funfstuck R, Stein G, Grone HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol 2004 61: 30 39.
8. Yun JJ, Whiting D, Fischbein MP et al. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation 2004 109: 932 937.
9. Reynaud-Gaubert M, Marin V, Thirion X et al. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration. J Heart Lung Transplant 2002 21: 721 730.
10. Belperio JA, Burdick MD, Keane MP et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 2000 165: 461 472.
11. Belperio JA, Keane MP, Burdick MD et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001 108: 547 556.
12. Berry GJ, Brunt EM, Chamberlain D et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990 9: 593 601.
13. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996 15 (1 Pt 1 1 15.
14. Palmer SM, Burch LH, Davis RD et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003 168: 628 632.
15. Cooper JD, Billingham M, Egan T et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993 12: 713 716.
16. Belperio JA, Keane MP, Burdick MD et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005 115: 1150 1162.
17. Kao J, Kobashigawa J, Fishbein MC et al. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 2003 107: 1958 1961.
18. Dmitrienko A, Molenberghs G, Chuang-Stein C, Offen W. Analysis of clinical trials using Sas: A Practical Guide SAS, 2005.
19. Monti G, Magnan A, Fattal M et al. Intrapulmonary production of RANTES during rejection and CMV pneumonitis after lung transplantation. Transplantation 1996 61: 1757 1762.
20. Gao W, Faia KL, Csizmadia V et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001 72: 1199 1205.
21. Fischereder M, Luckow B, Hocher B et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001 357: 1758 1761.
22. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998 338: 436 445.
23. Abonyo BO, Lebby KD, Tonry JH, Ahmad M, Heiman AS. Modulation of eotaxin-3 (CCL26) in alveolar type II epithelial cells. Cytokine 2006 36: 237 244.
24. Fairchild RL, VanBuskirk AM, Kondo T, Wakely ME, Orosz CG. Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation 1997 63: 1807 1812.
25. Yousem SA. The potential role of mast cells in lung allograft rejection. Hum Pathol 1997 28: 179 182.
26. Helantera I, Koskinen P, Finne P et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006 19: 893 900.
27. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004 66: 329 337.
28. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJ, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992 16: 285 292.
29. Lautenschlager I, Hockerstedt K, Jalanko H et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997 25: 190 194.
30. Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG study group. Ann Intern Med 1997 126: 275 279.
31. de Otero J, Gavalda J, Murio E et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998 26: 865 870.
32. Danziger-Isakov LA, DelaMorena M, Hayashi RJ et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003 75: 1538 1543.
33. Koskinen PK, Nieminen MS, Krogerus LA et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant 1993 12: 724 729.
34. Lemstrom KB, Koskinen PK, Bruning JH, Bruggeman CA, Lautenschlager IT, Hayry PJ. Effect of ganciclovir prophylaxis on cytomegalovirus-enhanced allograft arteriosclerosis. Transpl Int 1994 7 (Suppl 1 S383 384.
35. McLaughlin K, Wu C, Fick G, Muirhead N, Hollomby D, Jevnikar A. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002 74: 813 816.
36. Sageda S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transpl 2002 2: 850 856.
37. Duncan SR, Paradis IL, Yousem SA et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992 146: 1419 1425.
38. Duncan AJ, Dummer JS, Paradis IL et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991 10 (5 Pt 1 638 644 discussion 645-636.
39. Bando K, Paradis IL, Komatsu K et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995 109: 49 57 discussion 57-49.
40. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM, 3rd. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997 114: 195 202.
41. Cook DN, Beck MA, Coffman TM et al. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995 269: 1583 1585.
42. Domachowske JB, Bonville CA, Gao JL, Murphy PM, Easton AJ, Rosenberg HF. The chemokine macrophage-inflammatory protein-1 alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection. J Immunol 2000 165: 2677 2682.
43. Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine-to-cytokine-to- chemokine cascade critical in antiviral defense. J Clin Invest 2000 105: 985 993.
44. Panoskaltsis-Mortari A, Hermanson JR, Taras E, Wangensteen OD, Serody JS, Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 alpha (CCL3) after allogeneic BMT in mice. Blood 2003 101: 3714 3721.
45. Tamm M, Aboyoun CL, Chhajed PN, Rainer S, Malouf MA, Glanville AR. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004 170: 1120 1123.
46. Arena A, Stassi G, Speranza A, Iannello D, Mastroeni P. Modulatory effect of HHV-6 on MCP-1 production by human monocytes. New Microbiol 2002 25: 335 340.
47. Caruso A, Favilli F, Rotola A et al. Human herpesvirus-6 modulates RANTES production in primary human endothelial cell cultures. J Med Virol 2003 70: 451 458.
48. Neurohr C, Huppmann P, Leuchte H et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: A risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005 5: 2982 2991.
49. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007 26: 41 47.
50. Belperio JA, Keane MP, Burdick MD et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol 2005 175: 6931 6939.
51. Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005 171: 1312 1316.